Psychosocial treatments for relapse prevention in schizophrenia: study protocol for a systematic review and network meta-analysis of randomised evidence
Introduction There is evidence that different psychosocial interventions could reduce the risk of relapse in schizophrenia, but a comprehensive evidence based on their relative efficacy is lacking. We will conduct a network meta-analysis (NMA), integrating direct and indirect comparisons from random...
Saved in:
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMJ Publishing Group
2020-01-01
|
| Series: | BMJ Open |
| Online Access: | https://bmjopen.bmj.com/content/10/1/e035073.full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1846141989748211712 |
|---|---|
| author | Toshi A Furukawa Georgia Salanti Corrado Barbui Irene Bighelli Alessandro Rodolico Gabi Pitschel-Walz Wulf-Peter Hansen Stefan Leucht |
| author_facet | Toshi A Furukawa Georgia Salanti Corrado Barbui Irene Bighelli Alessandro Rodolico Gabi Pitschel-Walz Wulf-Peter Hansen Stefan Leucht |
| author_sort | Toshi A Furukawa |
| collection | DOAJ |
| description | Introduction There is evidence that different psychosocial interventions could reduce the risk of relapse in schizophrenia, but a comprehensive evidence based on their relative efficacy is lacking. We will conduct a network meta-analysis (NMA), integrating direct and indirect comparisons from randomised controlled trials (RCTs) to rank psychosocial treatments for relapse prevention in schizophrenia according to their efficacy, acceptability and tolerability.Methods and analysis We will include all RCTs comparing a psychosocial treatment aimed at preventing relapse in patients with schizophrenia with another psychosocial intervention or with a no treatment condition (waiting list, treatment as usual). We will include studies on adult patients with schizophrenia, excluding specific subpopulations (eg, acutely ill patients). Primary outcome will be the number of patients experiencing a relapse. Secondary outcomes will be acceptability (dropout), change in overall, positive, negative and depressive symptoms, quality of life, adherence, functioning and adverse events. Published and unpublished studies will be sought through database searches, trial registries and websites. Study selection and data extraction will be conducted by at least two independent reviewers. We will conduct random-effects NMA to synthesise all evidence for each outcome and obtain a comprehensive ranking of all treatments. NMA will be conducted in R within a frequentist framework. The risk of bias in studies will be evaluated using the Cochrane Risk of Bias tool and the credibility of the evidence will be evaluated using Confidence in Network Meta-Analysis (CINeMA). Subgroup and sensitivity analyses will be conducted to assess the robustness of the findings.Ethics and dissemination No ethical issues are foreseen. Results from this study will be published in peer-reviewed journals and presented at relevant conferences.PROSPERO registration number CRD42019147884. |
| format | Article |
| id | doaj-art-99f079f846234ac29df5becee7fd898d |
| institution | Kabale University |
| issn | 2044-6055 |
| language | English |
| publishDate | 2020-01-01 |
| publisher | BMJ Publishing Group |
| record_format | Article |
| series | BMJ Open |
| spelling | doaj-art-99f079f846234ac29df5becee7fd898d2024-12-03T22:15:09ZengBMJ Publishing GroupBMJ Open2044-60552020-01-0110110.1136/bmjopen-2019-035073Psychosocial treatments for relapse prevention in schizophrenia: study protocol for a systematic review and network meta-analysis of randomised evidenceToshi A Furukawa0Georgia Salanti1Corrado Barbui2Irene Bighelli3Alessandro Rodolico4Gabi Pitschel-Walz5Wulf-Peter Hansen6Stefan Leucht7Department of Health Promotion and Human Behavior, Kyoto University Graduate School of Medicine/School of Public Health, Kyoto, Japan3 Institute of Social and Preventive Medicine, University of Bern, Bern, SwitzerlandDepartment of Neurosciences, Biomedicine and Movement Sciences, Section of Psychiatry, University of Verona, Verona, ItalyDepartment of Psychiatry and Psychotherapy, School of Medicine, Klinikum rechts der Isar der Technischen Universitat Munchen, Munchen, GermanyDepartment of Clinical and Experimental Medicine, Institute of Psychiatry, University of Catania, Catania, Sicilia, ItalyDepartment of Psychiatry and Psychotherapy, School of Medicine, Klinikum rechts der Isar der Technischen Universitat Munchen, Munchen, GermanyBASTA - Bündnis für psychisch erkrankte Menschen, Munich, Germany1 Department of Psychiatry and Psychotherapy, School of Medicine and Health, Technical University of Munich, Munich, Bavaria, GermanyIntroduction There is evidence that different psychosocial interventions could reduce the risk of relapse in schizophrenia, but a comprehensive evidence based on their relative efficacy is lacking. We will conduct a network meta-analysis (NMA), integrating direct and indirect comparisons from randomised controlled trials (RCTs) to rank psychosocial treatments for relapse prevention in schizophrenia according to their efficacy, acceptability and tolerability.Methods and analysis We will include all RCTs comparing a psychosocial treatment aimed at preventing relapse in patients with schizophrenia with another psychosocial intervention or with a no treatment condition (waiting list, treatment as usual). We will include studies on adult patients with schizophrenia, excluding specific subpopulations (eg, acutely ill patients). Primary outcome will be the number of patients experiencing a relapse. Secondary outcomes will be acceptability (dropout), change in overall, positive, negative and depressive symptoms, quality of life, adherence, functioning and adverse events. Published and unpublished studies will be sought through database searches, trial registries and websites. Study selection and data extraction will be conducted by at least two independent reviewers. We will conduct random-effects NMA to synthesise all evidence for each outcome and obtain a comprehensive ranking of all treatments. NMA will be conducted in R within a frequentist framework. The risk of bias in studies will be evaluated using the Cochrane Risk of Bias tool and the credibility of the evidence will be evaluated using Confidence in Network Meta-Analysis (CINeMA). Subgroup and sensitivity analyses will be conducted to assess the robustness of the findings.Ethics and dissemination No ethical issues are foreseen. Results from this study will be published in peer-reviewed journals and presented at relevant conferences.PROSPERO registration number CRD42019147884.https://bmjopen.bmj.com/content/10/1/e035073.full |
| spellingShingle | Toshi A Furukawa Georgia Salanti Corrado Barbui Irene Bighelli Alessandro Rodolico Gabi Pitschel-Walz Wulf-Peter Hansen Stefan Leucht Psychosocial treatments for relapse prevention in schizophrenia: study protocol for a systematic review and network meta-analysis of randomised evidence BMJ Open |
| title | Psychosocial treatments for relapse prevention in schizophrenia: study protocol for a systematic review and network meta-analysis of randomised evidence |
| title_full | Psychosocial treatments for relapse prevention in schizophrenia: study protocol for a systematic review and network meta-analysis of randomised evidence |
| title_fullStr | Psychosocial treatments for relapse prevention in schizophrenia: study protocol for a systematic review and network meta-analysis of randomised evidence |
| title_full_unstemmed | Psychosocial treatments for relapse prevention in schizophrenia: study protocol for a systematic review and network meta-analysis of randomised evidence |
| title_short | Psychosocial treatments for relapse prevention in schizophrenia: study protocol for a systematic review and network meta-analysis of randomised evidence |
| title_sort | psychosocial treatments for relapse prevention in schizophrenia study protocol for a systematic review and network meta analysis of randomised evidence |
| url | https://bmjopen.bmj.com/content/10/1/e035073.full |
| work_keys_str_mv | AT toshiafurukawa psychosocialtreatmentsforrelapsepreventioninschizophreniastudyprotocolforasystematicreviewandnetworkmetaanalysisofrandomisedevidence AT georgiasalanti psychosocialtreatmentsforrelapsepreventioninschizophreniastudyprotocolforasystematicreviewandnetworkmetaanalysisofrandomisedevidence AT corradobarbui psychosocialtreatmentsforrelapsepreventioninschizophreniastudyprotocolforasystematicreviewandnetworkmetaanalysisofrandomisedevidence AT irenebighelli psychosocialtreatmentsforrelapsepreventioninschizophreniastudyprotocolforasystematicreviewandnetworkmetaanalysisofrandomisedevidence AT alessandrorodolico psychosocialtreatmentsforrelapsepreventioninschizophreniastudyprotocolforasystematicreviewandnetworkmetaanalysisofrandomisedevidence AT gabipitschelwalz psychosocialtreatmentsforrelapsepreventioninschizophreniastudyprotocolforasystematicreviewandnetworkmetaanalysisofrandomisedevidence AT wulfpeterhansen psychosocialtreatmentsforrelapsepreventioninschizophreniastudyprotocolforasystematicreviewandnetworkmetaanalysisofrandomisedevidence AT stefanleucht psychosocialtreatmentsforrelapsepreventioninschizophreniastudyprotocolforasystematicreviewandnetworkmetaanalysisofrandomisedevidence |